Analyzing Chinese Market from the Perspective of the New Drugs in China: An Empirical Study of Hepatitis B New Drugs

• Main Authors: Hsieh, Cheng-Hsueh, 謝政學
• Other Authors: Lin, Bou-Wen
• Format: Others
• Language: zh-TW
• Published: 2017
• Online Access: http://ndltd.ncl.edu.tw/handle/edkcft

碩士 === 國立清華大學 === 科技管理研究所 === 105 === New drug development is a popular issue in Taiwan recently. However, ingredient of a candidate of new drug is not limited by compound. On the other hand, firms which have ability to develop new drugs are increasing year by year. These are the main reasons that effect the environment of new drug development. Moreover, some disease such as Hepatitis B is regional. For instance, Hepatitis B is a common disease in China where contribute the most population of patient all over the world. Due to the policy and patients who have abilities to have treatment is increased, China become a high-potential market of drug of Hepatitis B. This research analyzed the market of China in a view of new drug entry. Collected data and discover the key effect of market of China according the concept of action research. Competitor analysis of Hepatitis B drugs which are available in China and new drugs which are under clinical trial are also discussed in this research. Finally, the suggestions of enter the market are provided based on the drugs and firms. The conclusion of the whole market analysis is at the end of the research.